Literature DB >> 2373763

Induction of chronic relapsing experimental allergic encephalomyelitis in Biozzi mice.

D Baker1, J K O'Neill, S E Gschmeissner, C E Wilcox, C Butter, J L Turk.   

Abstract

Experimental allergic encephalomyelitis (EAE) was induced in Biozzi AB/H (antibody high) mice by sensitization with spinal cord homogenate in adjuvant. Biozzi AB/H mice were highly susceptible to EAE induction and followed a chronic relapsing pattern of disease. Disease episodes were characterized by mononuclear infiltration of the central nervous system, with demyelination being particularly evident in relapse. The cellular infiltrates, which were associated with immunoglobulin deposition, consisted of macrophages and primarily CD4-positive T lymphocytes. However, similarly treated Biozzi AB/L (antibody low) mice were markedly less susceptible to EAE induction than AB/H mice. Thus, Biozzi mice should prove valuable for the study of chronic relapsing EAE.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2373763     DOI: 10.1016/0165-5728(90)90019-j

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  37 in total

Review 1.  T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.

Authors:  Kate O'Brien; Bruno Gran; Abdolmohamad Rostami
Journal:  Immunotherapy       Date:  2010-01       Impact factor: 4.196

2.  IL-10 is essential for disease protection following intranasal peptide administration in the C57BL/6 model of EAE.

Authors:  Emma J O'Neill; Michael J Day; David C Wraith
Journal:  J Neuroimmunol       Date:  2006-07-26       Impact factor: 3.478

3.  Serum levels of 25-hydroxy vitamin D in normal Biozzi and C57BL/6 mice and during the course of chronic relapsing experimental autoimmune encephalomyelitis (CR EAE).

Authors:  Christopher Bolton; Janet Gates; Gavin Giovannoni
Journal:  Inflamm Res       Date:  2013-04-20       Impact factor: 4.575

Review 4.  The endocannabinoid system as a target for the treatment of neurodegenerative disease.

Authors:  Emma L Scotter; Mary E Abood; Michelle Glass
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

5.  Cyclooxygenase expression and prostaglandin levels in central nervous system tissues during the course of chronic relapsing experimental autoimmune encephalomyelitis (EAE).

Authors:  Samir S Ayoub; Elizabeth G Wood; Sabih-Ul Hassan; Christopher Bolton
Journal:  Inflamm Res       Date:  2011-06-12       Impact factor: 4.575

6.  Expression of vascular addressins and ICAM-1 by endothelial cells in the spinal cord during chronic relapsing experimental allergic encephalomyelitis in the Biozzi AB/H mouse.

Authors:  J K O'Neill; C Butter; D Baker; S E Gschmeissner; G Kraal; E C Butcher; J L Turk
Journal:  Immunology       Date:  1991-04       Impact factor: 7.397

7.  Complete characterization of the expressed immune response genes in Biozzi AB/H mice: structural and functional identity between AB/H and NOD A region molecules.

Authors:  G Y Liu; D Baker; S Fairchild; F Figueroa; R Quartey-Papafio; M Tone; D Healey; A Cooke; J L Turk; D C Wraith
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

8.  Brain antigens in functionally distinct antigen-presenting cell populations in cervical lymph nodes in MS and EAE.

Authors:  Marloes van Zwam; Ruth Huizinga; Marie-José Melief; Annet F Wierenga-Wolf; Marjan van Meurs; Jane S Voerman; Knut P H Biber; Hendrikus W G M Boddeke; Uta E Höpken; Christian Meisel; Andreas Meisel; Ingo Bechmann; Rogier Q Hintzen; Bert A 't Hart; Sandra Amor; Jon D Laman; Leonie A Boven
Journal:  J Mol Med (Berl)       Date:  2008-12-03       Impact factor: 4.599

Review 9.  Developing therapeutics for the treatment of multiple sclerosis.

Authors:  David J Virley
Journal:  NeuroRx       Date:  2005-10

10.  Control of immune-mediated disease of the central nervous system requires the use of a neuroactive agent: elucidation by the action of mitoxantrone.

Authors:  D Baker; J K O'Neill; A N Davison; J L Turk
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.